Correction: Inclusion of patient-centered, non-microbiological endpoints and biomarkers in tuberculosis drug trials
Andrew R. DiNardo, Wilbert Sabiiti, Stephen H. Gillespie, Sophia B. Georghiou, Norbert Heinrich, Norbert Hittel, Sami Taghlabi, Danna Carrero Longlax, Mikashmi Kohli, Ursula Panzner, Collins Musia, Christoph Lange, Anca Vasiliu, Rob J. W. Arts, Anna M. Mandalakas, Morten Ruhwald
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
- —Deutsches Zentrum für Infektionsforschung10.13039/100009139
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsTuberculosis Research and Epidemiology · Diagnosis and treatment of tuberculosis · Biosimilars and Bioanalytical Methods
An incorrect Funding statement was provided. The correct Funding statement reads:
“This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 101007873. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA, Deutsches Zentrum für Infektionsforschung e. V. (DZIF), and Ludwig-Maximilians-Universität München (LMU). EFPIA/AP contribute to 50% of funding, whereas the contribution of DZIF and the LMU University Hospital Munich has been granted by the German Federal Ministry of Education and Research”.
The original version of this article has been updated.